NDC product
Lamotrigine Extended-Release
NDC 10370-256 · Par Health USA, LLC
Key facts
| Product NDC | 10370-256 |
|---|---|
| Proprietary name | Lamotrigine |
| Nonproprietary name | lamotrigine |
| Substances | LAMOTRIGINE |
| Dosage form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Par Health USA, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA201374 |
| Pharmacologic classes | Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE], Dihydrofolate Reductase Inhibitors [MoA], Mood Stabilizer [EPC], Organic Cation Transporter 2 Inhibitors [MoA] |
| Marketing start | Jan 2, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: